ARTICLE | Clinical News

Palonosetron: MOGN completed treatment of >1,800 patients undergoing moderately emetogenic chemotherapy in 3 double-blind and 1 open-label North American and Eu

January 22, 2002 8:00 AM UTC

MGI Pharma Inc. (MOGN), Minneapolis, Minn. Product: Palonosetron Business: Cancer Therapeutic category: Receptor antagonist, Adjunct Target: 5-HT3 serotonin receptors Description: Selective 5-HT3 sero...